Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung

#GNLX Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/GNLX/genelux-corpor...

Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock Genelux (Nasdaq: GNLX) priced an underwritten public offering of 6,666,667 common shares at $3.00 per share, for gross proceeds of approximately $20.0 million before underwriting discounts, commissions and expenses. The company granted a 30-day option for the underwriter to buy up to an additional 1,000,000 shares at the public price less discounts. Net proceeds are expected to be used for general corporate purposes, including R&D, clinical trial expenses, capital expenditures and working capital. The offering is expected to close on or about January 9, 2026, subject to customary closing conditions.

#GNLX Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock

www.stocktitan.net/news/GNLX/genelux-corpor...

Genelux Corporation Announces Proposed Public Offering of Common Stock Genelux (Nasdaq: GNLX) announced a proposed underwritten public offering of its common stock on January 7, 2026. The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares sold. All shares will be offered by Genelux and the offering is subject to market and customary closing conditions, so completion, size and terms are not assured. Lucid Capital Markets is the sole book-running manager. The offering will be made from an effective shelf registration filed February 2, 2024 and declared effective February 13, 2024, with a preliminary prospectus supplement to be filed with the SEC.

#GNLX Genelux Corporation Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/GNLX/genelux-corpor...

Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials Genelux (NASDAQ: GNLX) reported interim systemic Olvi-Vec data from ongoing lung cancer trials as of December 2025. In Phase 1b/2 SCLC (9 evaluable patients) the overall response rate was 33% (3/9), with two partial responses in the highest tested dose cohort showing ~55% and ~85% tumor shrinkage; disease control rate was 67% (6/9). In Phase 2 VIRO-25 NSCLC (5 evaluable patients) disease control rate was 60% (3/5) with tumor changes of +8.9%, -18.9%, and -22.7%. Olvi-Vec was reported as generally well tolerated. Additional lung cancer readouts and Phase 3 ovarian topline data expected throughout 2026.

#GNLX Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials

www.stocktitan.net/news/GNLX/genelux-corpor...

Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates -- Cash, cash equivalents, short-term investments and restricted cash of $21.0 million as of September

#GNLX Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates

www.stocktitan.net/news/GNLX/genelux-corpor...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new uptrend in Average Directional Index, Mon Jun 23rd - #INLF #GNLX #DWTX #VVOS #RFIL #PXLM #OLPX #NN #IMDX #CCNE #BASE #TXO #TEN #SQNS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates Genelux Corporation (NASDAQ: GNLX) reported Q1 2025 financial results and business updates. The company's lead candidate Olvi-Vec showed promising developments across multiple cancer indications. Key highlights include: FDA feedback indicating potential traditional approval for platinum-resistant/refractory ovarian cancer treatment pending Phase 3 trial results expected in 1H 2026; preliminary data from Phase 1b/2 trial showing 71% disease control rate in small cell lung cancer patients; and ongoing Phase 2 trial progress in non-small cell lung cancer. Financially, Q1 2025 showed a net loss of $7.5 million ($0.21 per share), with cash position of $35.1 million. The company completed a $10.5 million offering in March 2025, extending runway into Q3 2026. Matthew Pulisic joined as new CFO, bringing 19 years of biopharmaceutical industry experience.

#GNLX Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

www.stocktitan.net/news/GNLX/genelux-corpor...

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Genelux (NASDAQ: GNLX) reported its Q4 and full year 2024 financial results, highlighting key developments in its oncology pipeline. The company reached alignment with FDA on the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer, with topline data expected in H1 2026.In clinical developments, preliminary Phase 1b/2 data for Olvi-Vec in Advanced Small-Cell Lung Cancer showed a 71% disease control rate, with two partial responders and favorable safety profile. The company strengthened its financial position with a $10.5 million underwritten offering at $3.50 per share.Financial highlights include:Cash position of $30.9 million as of December 31, 2024R&D expenses increased to $19.0 million from $12.8 million in 2023G&A expenses rose to $12.7 million from $11.6 million in 2023Net loss of $29.9 million ($0.95 per share) compared to $28.3 million ($1.16 per share) in 2023

#GNLX Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/GNLX/genelux-corpor...

$10.5M Capital Raise: How Genelux Plans to Accelerate Cancer Drug Pipeline Immuno-oncology company secures crucial funding for Olvi-Vec clinical development through strategic stock offering. See investment implications.

#GNLX Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

www.stocktitan.net/news/GNLX/genelux-corpor...

Breakthrough: Cancer Drug Achieves 79% Tumor Reduction in Advanced Lung Cancer Study Latest clinical data reveals Olvi-Vec immunotherapy controls disease in 71% of advanced lung cancer patients, with up to 79% tumor reduction. Full analysis inside.

#GNLX Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer

www.stocktitan.net/news/GNLX/genelux-and-ne...

FDA Clears Streamlined Path for Genelux's Breakthrough Ovarian Cancer Treatment FDA signals potential traditional approval for Olvi-Vec without additional trials, boosting Genelux's ovarian cancer treatment timeline. Phase 3 data expected 2026.

#GNLX Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease

www.stocktitan.net/news/GNLX/genelux-announ...

Ex-Arrowhead & Amgen Executive Takes CFO Role at Genelux: Key Details on Strategic Appointment Genelux strengthens leadership team with Matthew Pulisic as CFO, bringing 19 years of global biopharma finance expertise from Arrowhead and Amgen to drive commercial growth.

#GNLX Genelux Corporation Announces New Chief Financial Officer

www.stocktitan.net/news/GNLX/genelux-corpor...

#NAMS #GNLX Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors

www.stocktitan.net/news/NAMS/frazier-life-s...

#GNLX Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates

www.stocktitan.net/news/GNLX/genelux-corpor...